How does SPDR S&P Biotech ETF (XBI) compare to competitors?

Lunoo provides objective, AI-powered comparisons. Use the comparison tool to see SPDR S&P Biotech ETF (XBI) side-by-side with any alternative.

zoom_in Click to enlarge

SPDR S&P Biotech ETF (XBI)

7.8

Good

language

description SPDR S&P Biotech ETF (XBI) Overview

XBI tracks the performance of biotechnology companies. The biotech sector is known for its volatility, making it attractive to short-term traders. The funds expense ratio is 0.35%. Regulatory approvals and clinical trial results can significantly impact stock prices, creating trading opportunities.

help SPDR S&P Biotech ETF (XBI) FAQ

What is SPDR S&P Biotech ETF (XBI)?

XBI tracks the performance of biotechnology companies. The biotech sector is known for its volatility, making it attractive to short-term traders. The funds expense ratio is 0.35%. Regulatory approvals and clinical trial results can significantly impact stock prices, creating trading opportunities.

How good is SPDR S&P Biotech ETF (XBI)?

SPDR S&P Biotech ETF (XBI) scores 7.8/10 (Good) on Lunoo, making it a well-rated option in the Finance category.

What are the best alternatives to SPDR S&P Biotech ETF (XBI)?

See our alternatives page for SPDR S&P Biotech ETF (XBI) for a ranked list with scores. Top alternatives include: iShares MSCI Emerging Markets ETF (EEM), WisdomTree U.S. Small-Cap ETF (DES), iShares Latin America ETF (ILAC).

How does SPDR S&P Biotech ETF (XBI) compare to iShares MSCI Emerging Markets ETF (EEM)?

See our detailed comparison of SPDR S&P Biotech ETF (XBI) vs iShares MSCI Emerging Markets ETF (EEM) with scores, features, and an AI-powered verdict.

Is SPDR S&P Biotech ETF (XBI) worth it in 2026?

With a score of 7.8/10, SPDR S&P Biotech ETF (XBI) is a solid option in Finance. See all Finance ranked.

swap_horiz

Looking for SPDR S&P Biotech ETF (XBI) alternatives? Compare top competitors ranked & scored

arrow_forward